These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 28414330)

  • 1. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.
    Honeycutt JB; Thayer WO; Baker CE; Ribeiro RM; Lada SM; Cao Y; Cleary RA; Hudgens MG; Richman DD; Garcia JV
    Nat Med; 2017 May; 23(5):638-643. PubMed ID: 28414330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
    Asahchop EL; Meziane O; Mamik MK; Chan WF; Branton WG; Resch L; Gill MJ; Haddad E; Guimond JV; Wainberg MA; Baker GB; Cohen EA; Power C
    Retrovirology; 2017 Oct; 14(1):47. PubMed ID: 29037245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy.
    Araínga M; Edagwa B; Mosley RL; Poluektova LY; Gorantla S; Gendelman HE
    Retrovirology; 2017 Mar; 14(1):17. PubMed ID: 28279181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
    Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
    J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring HIV Persistence on Antiretroviral Therapy.
    Horsburgh BA; Palmer S
    Adv Exp Med Biol; 2018; 1075():265-284. PubMed ID: 30030797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
    Li Q; Tso FY; Kang G; Lu W; Li Y; Fan W; Yuan Z; Destache CJ; Wood C
    J Acquir Immune Defic Syndr; 2015 Aug; 69(5):519-27. PubMed ID: 26167617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection dynamics and viral rebound: Modeling results from humanized mice.
    Guo T; Deng Q; Qiu Z; Rong L
    J Theor Biol; 2023 Jun; 567():111490. PubMed ID: 37054969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
    Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
    Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy.
    Ko A; Kang G; Hattler JB; Galadima HI; Zhang J; Li Q; Kim WK
    J Neuroimmune Pharmacol; 2019 Mar; 14(1):110-119. PubMed ID: 30194646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased recovery of replication-competent HIV-1 from peripheral blood mononuclear cell-derived monocyte/macrophages of HIV-positive patients after 3 years on highly active antiretroviral therapy.
    Belmonte L; Baré P; Picchio GR; Perez Bianco R; de Tezanos Pinto M; Corti M; Villafañe MF; de Bracco MM; Ruibal-Ares BH
    AIDS; 2002 Jun; 16(9):1289-92. PubMed ID: 12045497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Persistence on Antiretroviral Therapy and Barriers to a Cure.
    Sung JM; Margolis DM
    Adv Exp Med Biol; 2018; 1075():165-185. PubMed ID: 30030793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.